Cyclo Therapeutics Reports Positive Data From Phase 1 Study On Trappsol Cyclo For NPC Treatment

Cyclo Therapeutics Inc. (CYTH) announced new positive safety and efficacy data from ongoing phase 1 open-label extension study of trappsol cyclo for the treatment of niemann-pick disease type C1 or NPC. NPC is a rare, progressive and fatal genetic disorder characterized by abnormal accumulation of cholesterol in cells.

The data provide additional support for the capacity of Trappsol Cyclo to stabilize disease progression with home-based intravenous infusions in Niemann-Pick Disease Type C1, the company said in a statement.

Trappsol Cyclo is currently being evaluated in the pivotal Phase 3 study, TransportNPC, for the treatment of NPC1. Cyclo Therapeutics received Orphan Drug Designation for Trappsol Cyclo to treat NPC1 in both the US and EU and Fast Track and Rare Pediatric Disease Designations in the US.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
McDonald's says equal pay for women is just the beginning, while conforming that the fast-food giant pays women globally 99.85 cents on the dollar for similar work, taking into account legitimate pay drivers such as level, location, experience, and performance. The company added that it is on track to close that identified gap in 2022. Verizon Communications Inc. (VZ) said, on an adjusted basis, its third-quarter earnings per share rose 12.8 percent from a year ago. The company said its earnings were highlighted by revenue and customer growth as more than one in four Consumer wireless phone customers now have a 5G-capable device. The... While reporting financial results for the third quarter on Wednesday, Abbott Laboratories (ABT) raised its earnings and adjusted earnings guidance for the full-year 2021. For fiscal 2021, the company continues to project earnings from continuing operations in a range of $3.55 to $3.6 per share and...
Follow RTT